Seek Returns logo

DHR vs. GH: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at DHR and GH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolDHRGH
Company NameDanaher CorporationGuardant Health, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryLife Sciences Tools & ServicesHealth Care Providers & Services
Market Capitalization151.37 billion USD7.30 billion USD
ExchangeNYSENasdaqGS
Listing DateDecember 29, 1978October 4, 2018
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of DHR and GH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

DHR vs. GH: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolDHRGH
5-Day Price Return0.56%16.23%
13-Week Price Return7.63%40.59%
26-Week Price Return3.84%27.08%
52-Week Price Return-22.07%92.22%
Month-to-Date Return7.22%42.92%
Year-to-Date Return-7.91%91.72%
10-Day Avg. Volume3.11M4.09M
3-Month Avg. Volume4.00M2.42M
3-Month Volatility26.58%54.49%
Beta0.791.57

Profitability

Return on Equity (TTM)

DHR

6.69%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

DHR’s Return on Equity of 6.69% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

GH

-246.60%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

GH has a negative Return on Equity of -246.60%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

DHR vs. GH: A comparison of their Return on Equity (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Net Profit Margin (TTM)

DHR

14.21%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

DHR’s Net Profit Margin of 14.21% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

GH

-49.93%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

GH has a negative Net Profit Margin of -49.93%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

DHR vs. GH: A comparison of their Net Profit Margin (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Operating Profit Margin (TTM)

DHR

18.43%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

DHR’s Operating Profit Margin of 18.43% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

GH

-54.54%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

GH has a negative Operating Profit Margin of -54.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

DHR vs. GH: A comparison of their Operating Profit Margin (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Profitability at a Glance

SymbolDHRGH
Return on Equity (TTM)6.69%-246.60%
Return on Assets (TTM)4.28%-29.04%
Net Profit Margin (TTM)14.21%-49.93%
Operating Profit Margin (TTM)18.43%-54.54%
Gross Profit Margin (TTM)59.72%62.84%

Financial Strength

Current Ratio (MRQ)

DHR

1.62

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

DHR’s Current Ratio of 1.62 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

GH

3.71

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

GH’s Current Ratio of 3.71 is exceptionally high, placing it well outside the typical range for the Health Care Providers & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

DHR vs. GH: A comparison of their Current Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

DHR

0.33

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

GH

16.78

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

With a Debt-to-Equity Ratio of 16.78, GH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

DHR vs. GH: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Interest Coverage Ratio (TTM)

DHR

22.31

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

GH

-150.95

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

GH has a negative Interest Coverage Ratio of -150.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

DHR vs. GH: A comparison of their Interest Coverage Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Financial Strength at a Glance

SymbolDHRGH
Current Ratio (MRQ)1.623.71
Quick Ratio (MRQ)1.103.19
Debt-to-Equity Ratio (MRQ)0.3316.78
Interest Coverage Ratio (TTM)22.31-150.95

Growth

Revenue Growth

DHR vs. GH: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

DHR vs. GH: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

DHR

0.54%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

DHR’s Dividend Yield of 0.54% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.

GH

0.00%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

DHR vs. GH: A comparison of their Dividend Yield (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Dividend Payout Ratio (TTM)

DHR

23.85%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

DHR’s Dividend Payout Ratio of 23.85% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

GH

0.00%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

DHR vs. GH: A comparison of their Dividend Payout Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Dividend at a Glance

SymbolDHRGH
Dividend Yield (TTM)0.54%0.00%
Dividend Payout Ratio (TTM)23.85%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

DHR

44.40

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

DHR’s P/E Ratio of 44.40 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

GH

--

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

P/E Ratio data for GH is currently unavailable.

DHR vs. GH: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

DHR

6.31

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

DHR’s P/S Ratio of 6.31 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

GH

8.75

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

With a P/S Ratio of 8.75, GH trades at a valuation that eclipses even the highest in the Health Care Providers & Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

DHR vs. GH: A comparison of their Price-to-Sales Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

DHR

2.72

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

DHR’s P/B Ratio of 2.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

GH

35.72

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

At 35.72, GH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

DHR vs. GH: A comparison of their Price-to-Book Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Providers & Services industry benchmarks.

Valuation at a Glance

SymbolDHRGH
Price-to-Earnings Ratio (TTM)44.40--
Price-to-Sales Ratio (TTM)6.318.75
Price-to-Book Ratio (MRQ)2.7235.72
Price-to-Free Cash Flow Ratio (TTM)31.17--